GlaxoSmithKline halts Excedrin manufacturing over weighing issue by Eric Palmer Tuesday, January 21, 2020 Manufacturing issues have caused GlaxoSmithKline to halt production and distribution of Excedrin, which has led to outages at some pharmacies.
GSK cancer unit, in 'building mode,' gets picky with M&A by Carly Helfand Friday, January 17, 2020 Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.
GSK's Shingrix has only tapped part of a huge market: exec by Eric Sagonowsky Thursday, January 16, 2020 GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.
IPO or demerger? Pfizer, GSK contradict on consumer health JV by Angus Liu Thursday, January 16, 2020 Pfizer CEO says IPO, but GlaxoSmithKline's chief strategy officer says "all options are on the table" for the two companies' consumer joint venture.
With Tesaro expertise, GSK gears up for 3 oncology launches by Eric Sagonowsky Tuesday, January 14, 2020 GSK expects 3 regulatory approvals for cancer drugs in 2020, CEO Emma Walmsley said Tuesday at JPM.
JPM, Day 2: Sanofi, Lilly, Takeda, Pfizer and more by Tracy Staton, Kyle Blankenship Tuesday, January 14, 2020 It's still bright and early in San Francisco at the J.P. Morgan Healthcare Conference, but we have word on GSK launches, Amgen's Otezla and more.
AZ and Merck, racing against GSK, nab Lynparza 'priority' boost by Carly Helfand Monday, January 13, 2020 In a heated race against GSK in the PARP inhibitor market, AstraZeneca and Merck nabbed a helpful FDA boost for its Lynparza in ovarian cancer.
GSK's long-acting HIV injectable hits FDA snag by Angus Liu Monday, December 23, 2019 GSK's ViiV said the CRL is related to chemistry manufacturing and controls, not the drug's safety profile.
GSK consolidates Pfizer consumer brands under Publicis unit by Beth Snyder Bulik Friday, January 3, 2020 GSK has awarded Publicis Media and its bespoke platformGSK more business, adding the former Pfizer Consumer Healthcare brands to its portfolio.
Drugmakers' oncology, rare diseases rebrands may stay in 2020 by Kyle Blankenship Thursday, December 19, 2019 Lately, pharmas have been rebranding—more often than not, around oncology, rare diseases or both—and more could join the fold in 2020.
